The United Kingdom and the United States have hammered out a significant trade agreement that will preserve no import taxes on British pharmaceutical exports being sold in the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has pledged to increase funding on drugs through the NHS. This commitment secures that import taxes on these key goods will remain at nothing for a timeframe of 36 months.
This development follows previous statements to dramatically increase duties on patented drug products, with figures mentioned reaching 100%.
"This agreement with the UK reinforces the worldwide climate for cutting-edge drugs and introduces much-needed balance to U.S.–U.K. drug exports," an announcement noted.
Commercial Importance
Pharmaceuticals represent one of the Britain's biggest exports to the United States, which is easily the biggest buyer for leading UK drugmakers.
Trade data reveal that in the 12 months prior to September, the UK shipped drugs worth billions to the US. This figure accounted for 17.4% of British export trade in that span.
"This agreement protects employment, boosts capital expenditure and sets the stage for the UK to become a global hub for life sciences," the Business and Trade Secretary commented.
Key NHS Changes
The agreement entails several key commitments from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it deems new medicines to be unaffordable by a quarter.
- Higher Drug Budget: There is a goal to raise overall health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The percentage manufacturers must return to the NHS to prevent overspending will be restricted at 15%. Last year, repayments topped twenty percent.
Recent Tensions
The deal takes place against a ongoing row between the sector and the ministers over drug pricing and NHS adoption.
These tensions were intensified by claims that American patients were charged several times more for the same drugs than consumers in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or scrapped, while substantial investments have been pledged toward American operations.
A senior figure stated that the NHS needed to spend more on treatments, noting that its expenditure on drugs had declined as a share of its total funding over the last ten years.
